The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Dissenting Statement of Commissioner Christine S. Wilson Regarding the Issuance of a Notice of Penalty Offenses on Substantiation of Product Claims
Congressional Correspondence: March 31, 2023 - May 31, 2023
Prepared Statement of the Federal Trade Commission: Hearing on Compliance with Committee Oversight
Procedures for Oversight of the Horseracing Integrity and Safety Authority’s Annual Budget
2303003 Informal Interpretation
Dissenting Statement of Commissioner Christine S. Wilson regarding the Negative Option Rule NPRM
2303006 Informal Interpretation
2303004 Informal Interpretation
Public Workshop Examining Proposed Changes to the Ophthalmic Practice Rules (Eyeglass Rule)
Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al.
2303002 Informal Interpretation
Dalal A. Akoury d/b/a AWAREmed, et al., U.S. v.
In March 2023, the FTC took action under the Opioid Addiction Recovery Fraud Prevention Act, suing Dr. Dalal A. Akoury and a set of companies she controls that operate as AWAREmed Health & Wellness Resource Center, a medical clinic, for making a wide range of false or unsupported claims for addiction treatment services, cancer treatment services, and the treatment of other serious conditions. The proposed order settling the Commission’s complaint bars Dr. Akoury and her AWAREmed clinic from making such unsupported claims and requires her to pay a $100,000 civil penalty.
Dissenting Statement of Commissioner Christine S. Wilson In the Matter of Anchor Glass Container Corp
2303005 Informal Interpretation
BetterHelp, Inc.; Analysis of Proposed Consent Order To Aid Public Comment
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.